-
Dr. Margaret A. Liu, global expert in cancer vaccines, gene therapy and immunotherapy, Chief Executive Officer at PAX Therapeutics and member of several boards of directors
-
Anat Naschitz, seasoned life sciences investor and entrepreneur and co-founder of OrbiMed Israel
PARIS et CAMBRIDGE, Mass., 04 sept. 2024 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Company »), a French late-stage clinical-stage biotechnology company pioneering nanoparticle-based approaches to expand treatment options for patients with cancer and other diseases, today announced the appointment of Dr. Margaret A. Liu and Anat Naschitz as non-voting members of its Supervisory Board.
“We are excited about the opportunity to welcome Ms. Anat Naschitz and Dr. Margaret A. Liu to the Nanobiotix Supervisory Board as we continue to lead the development of nanoparticle therapies with high potential for the treatment of cancer and other major diseases,” said Laurent Lévy, Co-Founder and Chairman of the Executive Board of Nanobiotix. “Dr. Liu brings a wealth of experience in international academia, pharmaceuticals, biotechnology and public policy that will be valuable to Nanobiotix’s vision at this important time in the Company’s history. Ms. Naschitz has world-class expertise in raising and deploying capital to support disruptive innovation for the benefit of patients, healthcare professionals and investors.”
Margaret A. Liu, M.D., D.Sc.hc, M.D.hc. is a world-renowned expert in gene therapy, vaccines and immunotherapy. She is currently CEO of PAX Therapeutics and an Adjunct Full Professor at the University of California, San Francisco, and holds an honorary doctorate with a scientific affiliation in the Department of Medicine at Karolinska Institutet. Dr. Liu has pioneered bispecific antibodies and DNA vaccines, and has received numerous international awards. Dr. Liu regularly advises companies and governmental and non-governmental scientific organizations such as the World Health Organization (WHO) through her activities as Director of ProTherImmune and previously held positions of increasing responsibility at Merck & Co. and Chiron Corporation. She is currently a member of the Board of Directors of Ipsen, where she chairs the Ethics and Governance Committee and is a member of the Innovation and Development Committee, as well as a Board Member and President Emeritus of the International Vaccine Society. She is also a member of the Board of Directors of MacroGenics where she is also a member of the Science and Technology Committee. Previously, she served on the Supervisory Boards of Transgene, Sangamo Biosciences, Adjuvance Technologies, and the International Vaccine Institute and was a Senior Advisor in Vaccinology at the Bill & Melinda Gates Foundation. Dr. Liu received her MD from Harvard Medical School and completed her internship and residency in internal medicine followed by a fellowship in endocrinology at Massachusetts General Hospital. She has also served on the faculty of Harvard Medical School and was a visiting scientist at the Massachusetts Institute of Technology. She received a BA in Chemistry sum with praise you Colorado College.
Read more
Anat Naschitz is a life sciences investor and entrepreneur with over three decades of experience in biotechnology, pharmaceuticals, computational research, digital health and medical devices across multiple therapeutic areas and stages. Throughout her career, Ms. Naschitz has founded and grown companies to success through board membership, including at publicly traded companies, and through her involvement in their investment execution. Currently, she is the co-founder and CEO of 9xchange, a drug discovery informatics platform that uses artificial intelligence and machine learning to optimize biopharmaceutical assets. Ms. Naschitz also co-founded and co-led OrbiMed Israel, with an investment capacity of ± $17 billion, and previously worked at private equity firm Apax, with an investment capacity of ± €65 billion, where she invested in healthcare companies. Companies that Ms. Naschitz has developed and served as a director of include 89bio (Nasdaq: ETNB), which is currently conducting two Phase 3 cardiometabolic trials, which she led as a pharmaceutical spinout and was instrumental in taking public 18 months later, continuing to serve on the board and several committees; Azura Ophthalmics, in Phase 3 with a drug for meibomian gland disorder, the cause of most dry eye; and ForSight Vision 6, which is conducting a pivotal trial with a truly accommodating intraocular lens as part of a strategic alliance; TytoCare, a growth-stage company commercializing the Home Smart Clinic; and MDClone, commercializing a synthetic data and analytics platform. Earlier in her career, Ms. Naschitz was a partner at McKinsey in London, where she advised pharmaceutical companies on strategy, acquisitions and spin-offs. Sobi (STE: SOBI.ST) is the result of such a spin-off. Ms. Naschitz received her MBA from INSEAD and her LLB from Tel Aviv University.
“Ms. Naschitz and Dr. Liu have extensive international experience in the biopharmaceutical industry,” said Gary Phillips, MD, Chairman of the Supervisory Board of Nanobiotix. “We believe their expertise will strengthen our current strategic initiatives in oncology for NBTXR3 and expand development and collaboration opportunities for Nanobiotix platforms beyond NBTXR3.”
These appointments will be subject to ratification by Nanobiotix shareholders at the next general meeting.
About NANOBIOTIX
Nanobiotix is a late-stage, clinical-stage biotechnology company developing innovative physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients, backed by people committed to making a difference for humanity. Nanobiotix’s philosophy is rooted in the concept of pushing the boundaries of what is known to expand the possibilities of human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and has been listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York since December 2020. The Company has subsidiaries including one in Cambridge, Massachusetts (United States).
Nanobiotix owns over 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) central nervous system disorders.
For more information about Nanobiotix, visit www.nanobiotix.com or follow us on LinkedIn and Twitter.
Warning
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the anticipated completion of the Concurrent Private Placement by the Company and the additional shares to be subscribed by JJDC subject to required regulatory approvals. Words such as “expects,” “intends,” “may,” “could,” “plans,” “potential,” “should,” and “will” or the negative of these expressions and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the current expectations and assumptions of the Company’s management and on information currently available to it. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause Nanobiotix’s prospective results to differ materially, such as market conditions and risks related to Nanobiotix’s business and financial performance. Further information on risk factors that may affect the Company’s business and financial performance is set forth in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on April 24, 2024 under the heading “Item 3.D. Risk Factors”, in the 2023 Universal Registration Document filed with the AMF on April 24, 2024 and in any other filings made by Nanobiotix with the SEC, which are available on the SEC’s website at http://www.sec.gov/. The forward-looking statements included in this press release speak only as of the date of this press release and, except as required by applicable law, Nanobiotix undertakes no obligation to update such forward-looking information.
Contacts
Attachment
Related News :